statistiche ricercatore

Continente	#
NA - Nord America	397
EU - Europa	272
AS - Asia	270
SA - Sud America	63
Continente sconosciuto - Info sul continente non disponibili	42
AF - Africa	12
OC - Oceania	1
Totale	1.057

Nazione	#
US - Stati Uniti d'America	382
RU - Federazione Russa	97
SG - Singapore	96
IT - Italia	75
BR - Brasile	54
CN - Cina	53
HK - Hong Kong	39
VN - Vietnam	32
DE - Germania	23
BD - Bangladesh	20
GB - Regno Unito	16
FR - Francia	15
PL - Polonia	15
FI - Finlandia	13
CA - Canada	5
JP - Giappone	5
ZA - Sudafrica	5
AT - Austria	4
EC - Ecuador	4
ID - Indonesia	4
IE - Irlanda	4
IN - India	4
MX - Messico	4
KR - Corea	3
KZ - Kazakistan	3
PE - Perù	3
SE - Svezia	3
AZ - Azerbaigian	2
EG - Egitto	2
KE - Kenya	2
MY - Malesia	2
SV - El Salvador	2
TR - Turchia	2
AM - Armenia	1
AO - Angola	1
BG - Bulgaria	1
CL - Cile	1
CO - Colombia	1
CZ - Repubblica Ceca	1
DK - Danimarca	1
DZ - Algeria	1
ES - Italia	1
ET - Etiopia	1
HN - Honduras	1
IQ - Iraq	1
JM - Giamaica	1
KW - Kuwait	1
LV - Lettonia	1
NL - Olanda	1
NP - Nepal	1
PF - Polinesia Francese	1
PR - Porto Rico	1
SA - Arabia Saudita	1
TT - Trinidad e Tobago	1
UA - Ucraina	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	1.016

Nome	#
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge	175
Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement	170
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay	166
Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors	160
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome	149
T-Cell Receptor (TCR) repertoire as predictive biomarker of immune checkpoint inhibitor (ICI) response: a study on baseline features and dynamic evolution across multiple cancer types	146
Risk of cardiovascular toxicity with combination of immune-checkpoint inhibitors and angiogenesis inhibitors: a meta-analysis	91
Totale	1.057

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	53	0	0	1	0	12	2	0	4	3	16	10	5
2022/2023	96	4	18	1	14	13	13	1	14	6	3	6	3
2023/2024	77	0	11	5	10	1	15	4	12	0	7	2	10
2024/2025	185	1	16	10	10	10	14	28	14	9	26	19	28
2025/2026	596	74	27	37	56	52	83	79	44	30	35	53	26
2026/2027	42	21	6	15	0	0	0	0	0	0	0	0	0
Totale													1.057

Archivio istituzionale della ricerca dell'Università degli Studi di Palermo